• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Theratechnologies Inc.

    2/26/25 8:30:10 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THTX alert in real time by email
    6-K 1 d914050d6k.htm 6-K 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of February 2025.

    Commission File Number 001-35203

     

     

    Theratechnologies Inc.

    (Translation of registrant’s name into English)

     

     

    2015 Peel Street, Suite 1100

    Montreal, Quebec

    H3A 1T8, Canada

    (Address of principal executive office)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    ☒ Form 20-F   ☐ Form 40-F

     

     

     


    EXHIBIT INDEX

     

    Exhibit No.   

    Description of Exhibit

    99.1    Press Release Dated February 26, 2025


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    THERATECHNOLOGIES INC.
    By:   /s/ Jocelyn Lafond
    Name:   Jocelyn Lafond
    Title:   General Counsel and Corporate Secretary

    Date: February 26, 2025

    Get the next $THTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $THTX

    DatePrice TargetRatingAnalyst
    11/17/2022$9.00Overweight
    Cantor Fitzgerald
    7/29/2021$8.00 → $3.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $THTX
    Financials

    Live finance-specific insights

    See more
    • Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

      FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and LipodystrophyTotal Revenue $19 million, representing +17% growth year over yearFDA Approves Prior Approval Supplement (PAS) for EGRIFTA SV® sBLALatest from VAMOS study demonstrates excess visceral abdominal fat drives cardiovascular risk MONTREAL, April 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results for the first quarter 2025, ended February 28, 2025. All figures are in U.S. dollars unless otherwise stated. First-

      4/9/25 7:30:00 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

      MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results and provide a business update for its first quarter 2025 ended February 28 on Wednesday, April 9, 2025, at 8:30 a.m. ET. The call will be hosted by Paul Lévesque, President and Chief Executive Officer, who will be joined by other members of the management team, including Philippe Dubuc, Senior Vice President and Chief Financial Officer, Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer and John Leasure, Global Commercial Officer. Th

      4/3/25 4:30:00 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

      Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 million Achieved record quarterly revenue of $25 million and annual revenue of $85.9 million New credit facilities' favorable interest rates and amortization schedules free up approximately $19 million in cash in 2025 In-licensed two new Ionis assets in Canada to drive long-term growth MONTREAL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of

      2/26/25 7:30:00 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    SEC Filings

    See more
    • SEC Form 6-K filed by Theratechnologies Inc.

      6-K - Theratechnologies Inc. (0001512717) (Filer)

      5/2/25 4:30:17 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Theratechnologies Inc.

      6-K - Theratechnologies Inc. (0001512717) (Filer)

      4/16/25 10:51:02 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Theratechnologies Inc.

      6-K - Theratechnologies Inc. (0001512717) (Filer)

      4/15/25 11:47:51 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Theratechnologies Appoints Elina Tea to its Board of Directors

      MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Elina Tea, Chief Financial Officer at GLS North America, to its Board of Directors and as a member of the Company's Audit Committee. Ms. Tea will be Investissement Québec's designee pursuant to its investor rights agreement with the Company. "Elina Tea's extensive experience in finance, corporate strategy, and investor relations makes her a valuable addition to our Board of Directors," said Dawn Svoronos, Chair of the Board o

      4/5/24 11:00:00 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies Appoints Jordan Zwick to its Board of Directors

      MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and as a member of the Company's Audit Committee. "We welcome Jordan Zwick to the Board as an important addition to our esteemed group of advisors," said Dawn Svoronos, Chair of the Board of Directors at Theratechnologies. "With his extensive experience in the U.S. biotech and pharmaceutical industry, coupled with expertise in global

      3/21/24 8:00:00 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

      MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Alain Trudeau has resigned from the Board of Directors of Theratechnologies and as a member of its Audit Committee, effective immediately. "I want to thank Alain for his contributions to Theratechnologies as a director since joining the Company in October 2020 and for completing the annual review for the 2023 fiscal year", said Dawn Svoronos, Chair of the Board at Theratechnologies. "Alain was the current Chair of the Audit Committee

      2/29/24 4:34:00 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Theratechnologies Inc.

      SC 13G - Theratechnologies Inc. (0001512717) (Subject)

      2/14/24 4:51:41 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Theratechnologies Inc. (Amendment)

      SC 13G/A - Theratechnologies Inc. (0001512717) (Subject)

      2/7/24 6:55:18 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Theratechnologies Inc.

      SC 13D - Theratechnologies Inc. (0001512717) (Subject)

      11/28/23 4:52:43 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Theratechnologies with a new price target

      Cantor Fitzgerald initiated coverage of Theratechnologies with a rating of Overweight and set a new price target of $9.00

      11/17/22 7:27:25 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Theratechnologies from Buy to Hold and set a new price target of $3.00 from $8.00 previously

      7/29/21 9:53:58 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity reiterated coverage on Theratechnologies with a new price target

      Canaccord Genuity reiterated coverage of Theratechnologies with a rating of Buy and set a new price target of $8.00 from $7.00 previously

      4/19/21 9:31:33 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

      VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with combination tesamorelin/GLP-1 receptor agonist therapy MONTREAL, May 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced two poster presentations at the 19th Annual American Conference for the Treatment of HIV (ACTHIV 2025), taking place May 1-3 in Chicago, Ill. Both presentations focus on issues surrounding excess visceral abdominal fat (EVAF), a common comorbidity in people with HIV (PWH). One poster presents a new analysis of data from the Visceral Adiposity

      5/2/25 7:30:00 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies Provides Update on Sale Process

      MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced that following careful consideration of the current circumstances, including the publicly announced proposal from Future Pak, the Board of Directors of the Company (the "Board") has decided to further evaluate the potential sale of the Company through an open and non-exclusive process. In connection with this determination, the Board has authorized the special committee, consisting of independent and disinterested directors (the "Special Committee"), to oversee the process and make a recommendation t

      4/15/25 6:00:27 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soleus Capital Issues Letter to The Board of Theratechnologies

      Soleus Capital Management, L.P. ("Soleus Capital"), a healthcare investment firm which owns in excess of 10% of the stock of Theratechnologies Inc. (NASDAQ:THTX) (the "Company"), today sent a letter to the Board of Directors of the Company. In its letter, Soleus Capital described its belief that an acquisition of the Company is in the best interest of the Company's shareholders and urged the Board to pursue an acquisition offer announced earlier today by Future Pak, LLC at a price of at least $3.51 per share, representing a premium of at least 163% to the closing price of the Company on April 10th. The letter also described Soleus Capital's concern that management of the Company and the B

      4/12/25 8:46:00 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care